Andarz Fazlollahpour Naghibi

Dr. Andarz Fazlollahpour Naghibi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in Pathology - Research and Practice
Verified
Journal Article
Closed access
AKAnsar Karimian
Ansar Karimian
MMMaryam Majidinia
Maryam Majidinia
AMAfshin Moliani
Afshin Moliani
FAForough Alemi
Forough Alemi
ZAZatollah Asemi
Zatollah Asemi
ANAndarz Fazlollahpour Naghibi
Andarz Fazlollahpour Naghibi

25 May 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MFMohsen Karami Fath
Mohsen Karami Fath
NKNastaran Karimfar
Nastaran Karimfar
ANAndarz Fazlollahpour Naghibi
Andarz Fazlollahpour Naghibi
SSShahriyar Shafa
Shahriyar Shafa
MSMelika Ghasemi Shiran
Melika Ghasemi Shiran
VTVahideh Tarhriz
Vahideh Tarhriz
Cancer can be induced by a variety of possible causes, including tumor suppressor gene failure and proto-oncogene hyperactivation. Tumor-associated extrachromosomal circular DNA has been proposed to endanger human health and speed up the progression of cancer. The amplification of ecDNA has raised the oncogene copy number in numerous malignancies according to whole-genome sequencing on distinct cancer types. The unusual structure and function of ecDNA, and its potential role in understanding current cancer genome maps, make it a hotspot to study tumor pathogenesis and evolution. The discovery of the basic mechanisms of ecDNA in the emergence and growth of malignancies could lead researchers to develop new cancer therapies. Despite recent progress, different aspects of ecDNA require more investigation. We focused on the features, and analyzed the bio-genesis, and origin of ecDNA in this review, as well as its functions in neuroblastoma and glioma cancers.

22 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SKSaeed Khalili
Saeed Khalili
FZFatemeh Zeinali
Fatemeh Zeinali
AFAtousa Moghadam Fard
Atousa Moghadam Fard
STSeyed Reza Taha
Seyed Reza Taha
ANAndarz Fazlollahpour Naghibi
Andarz Fazlollahpour Naghibi
ZPZahra Payandeh
Zahra Payandeh
Macrophages are types of immune cells, with ambivalent functions in tumor growth, which depend on the specific environment in which they reside. Tumor-associated macrophages (TAMs) are a diverse population of immunosuppressive myeloid cells that play significant roles in several malignancies. TAM infiltration in malignancies has been linked to a poor prognosis and limited response to treatments, including those using checkpoint inhibitors. Understanding the precise mechanisms through which macrophages contribute to tumor growth is an active area of research as targeting these cells may offer potential therapeutic approaches for cancer treatment. Numerous investigations have focused on anti-TAM-based methods that try to eliminate, rewire, or target the functional mediators released by these cells. Considering the importance of these strategies in the reversion of tumor resistance to conventional therapies and immune modulatory vaccination could be an appealing approach for the immunosuppressive targeting of myeloid cells in the tumor microenvironment (TME). The combination of reprogramming and TAM depletion is a special feature of this approach compared to other clinical strategies. Thus, the present review aims to comprehensively overview the pleiotropic activities of TAMs and their involvement in various stages of cancer development as a potent drug target, with a focus on hematologic tumors.

1 May 2025 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
STSeyed Reza Taha
Seyed Reza Taha
ANAndarz Fazlollahpour Naghibi
Andarz Fazlollahpour Naghibi
MZMahdieh Shariat Zadeh
Mahdieh Shariat Zadeh
KBKimia Bagheri
Kimia Bagheri
HYHamed Rahmani Youshanlouei
Hamed Rahmani Youshanlouei
SMSaba Mehrtabar
Saba Mehrtabar
Treatment of hepatic diseases presents a significant challenge due to their diverse nature. Ginsenosides, bioactive compounds derived from the root of Panax ginseng and widely used in traditional Chinese medicine, offer multifaceted protection to various organs in the body. Their versatile effects, including antioxidant, anti-inflammatory, anti-apoptotic and more, make them a promising approach for addressing hepatic disorders. This review explores the intricate molecular mechanisms and properties of ginsenosides in the prevention and treatment of liver ailments, from mild conditions to severe damage and liver fibrosis. Given the increasing prevalence of hepatic disorders, this article sheds light on the significant pharmaceutical potential of ginsenosides in the realm of hepatic disease management.